Stock Scorer

TScan Therapeutics, Inc. (TCRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 2.5M 5M 7.5M Q3 '21: 2.4M Q4 '21: 2.9M Q1 '22: 3M Q2 '22: 4.1M Q3 '22: 3.4M Q4 '22: 3.1M Q1 '23: 6.8M Q2 '23: 3.1M Q3 '23: 3.9M Q4 '23: 7.2M Q1 '24: 566K Q2 '24: 536K Q3 '24: 1M Q4 '24: 665K Q1 '25: 2.2M Q2 '25: 3.1M Q3 '25: 2.5M Q4 '25: 2.6M Q1 '26: 982K Q2 '26: 1.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -15.8M Q4 '21: -14.2M Q1 '22: -16.2M Q2 '22: -15.2M Q3 '22: -16.6M Q4 '22: -18.6M Q1 '23: -22.7M Q2 '23: -24.6M Q3 '23: -24.7M Q4 '23: -21.4M Q1 '24: -31.4M Q2 '24: -34.1M Q3 '24: -32.6M Q4 '24: -36.7M Q1 '25: -36.2M Q2 '25: -38.7M Q3 '25: -37.1M Q4 '25: -23.9M Q1 '26: -29.1M Q2 '26: -30.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -15.8M Q4 '21: -14.2M Q1 '22: -16.2M Q2 '22: -15.1M Q3 '22: -16.2M Q4 '22: -18.7M Q1 '23: -22.6M Q2 '23: -24M Q3 '23: -23M Q4 '23: -19.6M Q1 '24: -30.1M Q2 '24: -31.7M Q3 '24: -29.9M Q4 '24: -35.8M Q1 '25: -34.1M Q2 '25: -37M Q3 '25: -35.7M Q4 '25: -23M Q1 '26: -28.7M Q2 '26: -30.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -13.6M Q4 '21: -14.4M Q1 '22: -20.1M Q2 '22: -13.4M Q3 '22: -17M Q4 '22: -16M Q1 '23: -23.6M Q2 '23: -22M Q3 '23: 8M Q4 '23: -23.8M Q1 '24: -29.3M Q2 '24: -26.2M Q3 '24: -27.9M Q4 '24: -27.4M Q1 '25: -37.6M Q2 '25: -33.3M Q3 '25: -32.5M Q4 '25: -32M Q1 '26: -24.3M Q2 '26: -27.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -14.5M Q4 '21: -16.6M Q1 '22: -20.7M Q2 '22: -15.3M Q3 '22: -17.4M Q4 '22: -17.4M Q1 '23: -24.4M Q2 '23: -22.4M Q3 '23: 6.6M Q4 '23: -24.2M Q1 '24: -30M Q2 '24: -27.1M Q3 '24: -29.3M Q4 '24: -28.3M Q1 '25: -39.1M Q2 '25: -34.5M Q3 '25: -33.9M Q4 '25: -32.2M Q1 '26: -24.3M Q2 '26: -28M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '21: 1.4M Q3 '21: 19.9M Q1 '22: 24M Q2 '22: 24.1M Q3 '22: 24.1M Q1 '23: 24.2M Q2 '23: 47.2M Q3 '23: 94.8M Q1 '24: 94.9M Q2 '24: 113.4M Q3 '24: 118.7M Q1 '25: 129.7M Q2 '25: 129.7M Q3 '25: 129.8M Q1 '26: 129.9M Q2 '26: 129.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q3 '21: -23.06 Q4 '21: -4.17 Q1 '22: 1.65 Q2 '22: 8.71 Q3 '22: 8.84 Q4 '22: -2.74 Q1 '23: -3.00 Q2 '23: -2.88 Q3 '23: -2.45 Q4 '23: -1.79 Q1 '24: -1.18 Q2 '24: -0.95 Q3 '24: -0.96 Q4 '24: -1.15 Q1 '25: -1.09 Q2 '25: -1.09 Q3 '25: -1.12 Q4 '25: -1.00 Q1 '26: -0.96 Q2 '26: -0.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for TCRX: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.